Want to see LGVN full AI Analyst Report?
LGVN Stock Chart & Stats
$0.68
>-$0.01(-1.19%)
At close: 4:00 PM EDT
$0.68
>-$0.01(-1.19%)
Day’s Range― - ―
52-Week Range$1.31 - $12.30
Previous CloseN/A
Volume160.25K
Average Volume (3M)149.59K
Market Cap
$5.10M
Enterprise Value$12.56M
Total Cash (Recent Filing)$10.08M
Total Debt (Recent Filing)$581.00K
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Nov 06, 2026EPS Estimate
-1.95Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.10
Shares Outstanding3,043,297
10 Day Avg. Volume79,547
30 Day Avg. Volume149,592
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.57
Price to Sales (P/S)7.42
P/FCF Ratio-0.47
Enterprise Value/Market Cap2.46
Enterprise Value/Revenue10.58
Enterprise Value/Gross Profit15.17
Enterprise Value/Ebitda-0.55
Forecast
1Y Price Target
$30.00Price Target Upside4311.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-7.13
Revenue Forecast (FY)$1.52M
Bulls Say, Bears Say
Bulls Say
Regulatory And IP StrengthThe broad patent portfolio and multiple FDA expedited designations can protect development efforts and support more efficient regulatory engagement. These assets strengthen the company’s strategic position across indications and may improve partnering prospects as programs advance through clinical development.
PDCM Development ProgressAn effective IND and a potential direct path into a registrational Phase 2 trial provide a defined development route for pediatric dilated cardiomyopathy. This regulatory progress could accelerate value creation if clinical execution remains successful and the program produces supportive efficacy data.
Low Financial LeverageVery low leverage limits interest burden and reduces the risk that debt obligations constrain clinical investment. Although the company remains dependent on external funding, a lightly leveraged balance sheet gives management more flexibility than a debt-heavy structure while pursuing partnerships or financing.
Bears Say
ELPIS II Efficacy MissThe primary endpoint miss materially weakens the lead program’s original development case and makes regulatory advancement in hypoplastic left heart syndrome less certain. The resulting strategic review and refocus increase the risk that prior clinical investment will not translate into commercialization.
Limited Cash RunwayA runway extending only into the fourth quarter of 2026 creates a near-term financing or partnership requirement while clinical programs remain active. Funding needs may force difficult prioritization, increase dilution risk, or slow development if additional capital is not secured on acceptable terms.
Minimal Revenue And Widening LossesThe very small and declining revenue base provides little operating support for ongoing research, while widening losses indicate that expenses continue to outpace available inflows. This weak earnings profile limits self-funded growth and leaves the business reliant on financing, grants, or strategic partners.
Longeveron News
LGVN FAQ
What was Longeveron’s price range in the past 12 months?
Longeveron lowest stock price was $1.31 and its highest was $12.30 in the past 12 months.
What is Longeveron’s market cap?
Longeveron’s market cap is $5.10M.
When is Longeveron’s upcoming earnings report date?
Longeveron’s upcoming earnings report date is Nov 06, 2026 which is in 12 days.
How were Longeveron’s earnings last quarter?
Longeveron released its earnings results on Aug 12, 2026. The company reported -$1.9 earnings per share for the quarter, missing the consensus estimate of -$1.75 by -$0.15.
Is Longeveron overvalued?
According to Wall Street analysts Longeveron’s price is currently Undervalued.
Does Longeveron pay dividends?
Longeveron does not currently pay dividends.
What is Longeveron’s EPS estimate?
Longeveron’s EPS estimate is -1.95.
How many shares outstanding does Longeveron have?
Longeveron has 3,043,297 shares outstanding.
What happened to Longeveron’s price movement after its last earnings report?
Longeveron reported an EPS of -$1.9 in its last earnings report, missing expectations of -$1.75. Following the earnings report the stock price went down -6.601%.
Which hedge fund is a major shareholder of Longeveron?
Currently, no hedge funds are holding shares in LGVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Longeveron
Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesses. The company's primary investigational product is LOMECEL-B, a sophisticated cellular therapy. This product is created from medicinal signaling cells that are cultivated and expanded after being harvested from the bone marrow of healthy young adult donors. Longeveron is actively conducting Phase 1 and Phase 2 clinical trials to evaluate LOMECEL-B's potential across a diverse range of indications. These include age-related frailty, Alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Established in 2014, Longeveron Inc. operates from its headquarters in Miami, Florida.
LGVN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced meaningful scientific, regulatory, and validation milestones (upcoming ELPIS II readout, XPRIZE finalist award, high-profile publications, strong IP and expedited designations, and regulatory progress for PDCM) against material financial constraints (very low revenues, rising expenses, widening net loss, and a cash runway into Q4 2026). The business outlook is highly dependent on the imminent trial readout and the company's ability to secure partnerships or financing to extend the runway and commercialize programs.View all LGVN earnings summariesLGVN Stock 12 Month Forecast
Average Price Target
$30.00
▲(4311.76% Upside)
Technical Analysis
Ibio
―
Edesa Biotech
―
Chemomab Therapeutics
―
Processa Pharmaceuticals
―
FibroBiologics, Inc.
―
Ownership Overview
20.12% Insiders
2.17% Mutual Funds
― Other Institutional Investors
75.80% Public Companies and
Individual Investors